Skip to main content

Table 1 Linear regression to analyze cisplatin and/or compound's effect on OVCAR-3 cell proliferation.

From: Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc

  Kaempferol α-Tocopherol Succinate Rutin Hydrate
R2 0.901 0.891 0.188
  B Sig. B Sig. B Sig.
Constant 2.002 0.000 2.010 0.000 2.009 0.000
Cisplatin -0.012 0.198 -0.019 0.040 -0.028 0.789
Compound -0.022 0.238 -0.048 0.006 -0.237 0.221
Cispl. × Comp. -0.058 0.001 -0.032 0.015 0.029 0.844
  Apigenin Taxifolin Luteolin
R2 0.947 0.415 0.841
  B Sig. B Sig. B Sig.
Constant 2.008 0.000 2.009 0.000 2.010 0.000
Cisplatin -0.015 0.119 -0.028 0.035 -0.019 0.076
Compound -0.173 0.000 -0.003 0.902 -0.102 0.000
Cispl. × Comp. 0.0080 0.571 0.003 0.884 0.008 0.548
  Naringin α-Tocopherol Genistein
R2 0.296 0.541 0.885
  B Sig. B Sig. B Sig.
Constant 2.009 0.000 2.010 0.000 2.010 0.000
Cisplatin -0.028 0.306 -0.019 0.521 -0.019 0.086
Compound -0.058 0.243 -0.062 0.253 -0.117 0.000
Cispl. × Comp. 0.001 0.989 -0.046 0.269 0.0001 0.994
  Quercetin     
R2 0.567     
  B Sig.     
Constant 2.010 0.000     
Cisplatin -0.019 0.467     
Compound -0.029 0.533     
Cispl. × Comp. -0.056 0.134     
  1. Data from 3 independent experiments were modeled as (Viability = Constant + Cisplatin + Compound + Cisplatin* Compound) to analyze effects of Cisplatin, Compound, and Cisplatin-Compound interactions. Tabulated are standardized coefficients (B) with corresponding p values (Sig.) for each model. The goodness of fit, R2, is also listed for each model.